Related references
Note: Only part of the references are listed.Population PK and Exposure-Response Relationships for the Antibody-Drug Conjugate Brentuximab Vedotin in CTCL Patients in the Phase III ALCANZA Study
Ajit Suri et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2018)
Challenges and Opportunities in Dose Finding in Oncology and Immuno-oncology
Yan Ji et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Brentuximab Vedotin with Chemotherapy for Stage III or IV Hodgkin's Lymphoma
J. M. Connors et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development
Stephanie Faucette et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2018)
Population Pharmacokinetics of Brentuximab Vedotin in Patients With CD30-Expressing Hematologic Malignancies
Hong Li et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Brentuximab vedotin or physician's choice in CD30-positive cutaneous T-cell lymphoma (ALCANZA): an international, open-label, randomised, phase 3, multicentre trial
H. Miles Prince et al.
LANCET (2017)
Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions
C. A. van der Weyden et al.
BLOOD CANCER JOURNAL (2017)
Brentuximab vedotin for treatment of non-Hodgkin lymphomas: A systematic review
Garrett K. Berger et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2017)
Pharmacokinetics of Monoclonal Antibodies
Josiah T. Ryman et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Model-Based Population Pharmacokinetic Analysis of Nivolumab in Patients With Solid Tumors
G. Bajaj et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2017)
Drug Development of Therapeutic Monoclonal Antibodies
Diane R. Mould et al.
BIODRUGS (2016)
Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma
Robert Chen et al.
BLOOD (2016)
Brentuximab vedotin, an antibody-drug conjugate, in patients with CD30-positive haematologic malignancies and hepatic or renal impairment
Baiteng Zhao et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Targeting CD30 Using Brentuximab Vedotin in the Treatment of Hodgkin Lymphoma
Anna Alperovich et al.
CANCER JOURNAL (2016)
Toward Optimum Benefit-Risk and Reduced Access Lag For Cancer Drugs in Asia: A Global Development Framework Guided by Clinical Pharmacology Principles
K. Venkatakrishnan et al.
CTS-CLINICAL AND TRANSLATIONAL SCIENCE (2016)
Human serum albumin homeostasis: a new look at the roles of synthesis, catabolism, renal and gastrointestinal excretion, and the clinical value of serum albumin measurements
David G. Levitt et al.
INTERNATIONAL JOURNAL OF GENERAL MEDICINE (2016)
Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial
Craig H. Moskowitz et al.
LANCET (2015)
Optimizing Oncology Therapeutics Through Quantitative Translational and Clinical Pharmacology: Challenges and Opportunities
K. Venkatakrishnan et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2015)
Developing Exposure/Response Models for Anticancer Drug Treatment: Special Considerations
D. R. Mould et al.
CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY (2015)
Population pharmacokinetics and exposure-response analyses of trastuzumab in patients with advanced gastric or gastroesophageal junction cancer
Valerie F. Cosson et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2014)
Phase I/II study of brentuximab vedotin in Japanese patients with relapsed or refractory CD30-positive Hodgkin's lymphoma or systemic anaplastic large-cell lymphoma
Michinori Ogura et al.
CANCER SCIENCE (2014)
Brentuximab vedotin combined with ABVD or AVD for patients with newly diagnosed Hodgkin's lymphoma: a phase 1, open-label, dose-escalation study
Anas Younes et al.
LANCET ONCOLOGY (2013)
A Phase I Weekly Dosing Study of Brentuximab Vedotin in Patients with Relapsed/Refractory CD30-Positive Hematologic Malignancies
Michelle A. Fanale et al.
CLINICAL CANCER RESEARCH (2012)
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Clinical Implications of Pathophysiological and Demographic Covariates on the Population Pharmacokinetics of Trastuzumab Emtansine, a HER2-Targeted Antibody-Drug Conjugate, in Patients With HER2-Positive Metastatic Breast Cancer
Manish Gupta et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas.
Anas Younes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Kinetics of FcRn-mediated recycling of IgG and albumin in human: Pathophysiology and therapeutic implications using a simplified mechanism-based model
Jonghan Kim et al.
CLINICAL IMMUNOLOGY (2007)
Share Paper
